Figure 2 | Scientific Reports

Figure 2

From: Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients

Figure 2

Molecular evaluation on the basis of the clinical stratification of ALS patients. Relative expression trend of genes (A) and microRNAs (B) in slow (with ≥4 years of disease progression without requiring respiratory support) and rapid (with <4 years of disease progression) ALS groups compared with controls. Relative expression trend of genes (C) and microRNAs (D) of early (less than one year from symptom onset to muscle biopsy) and late (more than one year from symptom onset to muscle biopsy) ALS groups and controls. All data were expressed as mean fold change ± SD across replicates, with control values set to 1. Unpaired t-test was used to detect the statistical significance between ALS and controls values; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Back to article page